Premature ovarian failure and dehydroepiandrosterone.
Since the first successful birth at our center following treatment with DHEA in a patient with premature ovarian failure (POF), all subsequent patients with POF underwent the same treatment protocol. Receiving very encouraging results (FSH level was decreased in the first five patients and all achieved pregnancy), it was decided to study the action of DHEA for a reasonable length of time and in a larger number of patients to confirm the effectiveness of this particular therapeutic regime.
Mamas
Leonidas
L
Neogenesis IVF Centre, Athens, Greece. leonidasmamas@neogenesis.gr
Mamas
Eudoxia
E
D000328:Adult; D003687:Dehydroepiandrosterone / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007986:Luteinizing Hormone / Q000097:blood; D010865:Pilot Projects; D011247:Pregnancy; D018873:Pregnancy Rate; D016649:Primary Ovarian Insufficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D003687:Dehydroepiandrosterone; D004958:Estradiol; D007986:Luteinizing Hormone